RSCM
SGMT icon

Rock Springs Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Rock Springs Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-787,808
Closed -$2.57M – 100
2025
Q1 		$2.57M Hold
787,808
– – 0.15% 75
2024
Q4 		$3.55M Hold
787,808
– – 0.14% 83
2024
Q3 		$2.18M Hold
787,808
– – 0.07% 97
2024
Q2 		$2.69M Buy
787,808
+17,137
+2% +$78.6K 0.08% 98
2024
Q1 		$4.18M Buy
770,671
+32,316
+4% +$232K 0.11% 96
2023
Q4 		$4M Hold
738,355
– – 0.1% 84
2023
Q3 		$6.5M Buy
+738,355
New +$9.83M 0.17% 80

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Rock Springs Capital Management's SGMT Position: Q2 2025 in Review

Rock Springs Capital Management sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 787,808 shares — an estimated $2.57M sold.

Rock Springs Capital Management first reported a position in SGMT in Q3 2023 and held it in 7 quarters. The position peaked at $6.5M in Q3 2023. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Rock Springs Capital Management reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 787,808 Sagimet Biosciences shares in Q2 2025, an estimated $2.57M.
  • Rock Springs Capital Management first reported a position in Sagimet Biosciences in Q3 2023 and held it in 7 quarters.
  • Rock Springs Capital Management's Sagimet Biosciences position peaked at $6.5M in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.